(Date:12/2/2009)... LIBREVILLE, Gabon, December 2 ,...yone,s Problem and Heritage" , Coinciding...June 2010 the,Gabonese Republic is hosting an inte...issue of safeguarding biological resources in Afri...and state leaders, ministers,scientific experts, ...
(Date:12/2/2009)..., SINGAPORE, Dec. 2 S*BIO Pte Ltd ...al JAK2 inhibitor, SB1518, at The American Society...in New Orleans. ,, Data will be presented on th...n trial of SB1518 detailing its safety, tolerabili...file in dose levels ranging from 100 to 600 mg. Th...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world... in turmoil and uncertainty is part of many,busine...industry has been,relatively immune to the economi...n. , During the midst of the difficult ti...mp; Johnson inaugurated an R&D center in Shang...
(Date:12/1/2009)...NE VILLAGE, Nev., Dec. 1 ...announced revenue guidance for the fourth quarter ...on, as compared with $69 million for the fourth qu...ults was the first of two installment payments of ...th quarter 2008 results was a one-time $1.8 millio...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3...ARUP Laboratories, a national,clinical and anatomi...nnovative laboratory research and development, ann...up purchasing agreement with Premier Purchasing,Pa...ng alliances of leading,hospitals and health care ... between ARUP and Premier which has been in effect...
...anoLogix, Inc. (OTC:,NNLX) is pleased to announce ...s Director of Intellectual Property. In addition, ...made in the rapid detection of,Anthrax utilizing t... has over seven years, experience as an intellectu...ndustries including the position of,Corporate Inte...
...27 Notice is hereby,given that the 2007 Annual Ge...olders of Rosetta Genomics Ltd. (NASDQ:ROSG) (the ...e offices of Yigal Arnon & Co., Azrieli,Center, Ro... September 24,2007, at 11:00 a.m. (Israel time) fo...ntment of Kost, Forer, Gabbay & Kasierer (a,member...
Other Biology Technology:ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services 2NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 2NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 3Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007 2...con's 3243 provides all the materials necessary fo...use in CMV antigen studies analysis. Kit Componen...22) One bottle containing 220 mL of buffered ammon...(Catalog No. 5113) One bottle containing 220 mL of...
Rabbit Anti-NO-TRYPTOPHAN CONJUGATE Polyclonal Antibody, Unconjugated from AbD Serotec
Goat Anti-Human SLI Polyclonal Antibody, Unconjugated from AbD Serotec
Mouse Anti-L-DIHYDROXYPHENYLALANINE (L-DOPA) CONJUGATE Monoclonal Antibody, Unconjugated from AbD Serotec
Biology Products: